PDCD1 and cancer: Immune checkpoint inhibitors, such as anti-programmed cell death-1 (PD-1) antibody, anti-programmed cell death ligand-1 (PD-L1) antibody, and cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody, have been widely used and are called cancer immunotherapeutic drugs [6,7].